UNIVERSITY OF BIRMINGHAM

Research at Birmingham

S14.5 The effects of 9-tetrahydrocannabinol on sympathetic cotransmission in the mouse vas deferens

Kennard, JAG; Sachdev, AR; Young, JS; Brain, Keith

DOI: 10.1016/j.autneu.2009.05.074

Document Version Peer reviewed version

Citation for published version (Harvard): Kennard, JAG, Sachdev, AR, Young, JS & Brain, K 2009, 'S14.5 The effects of 9-tetrahydrocannabinol on sympathetic cotransmission in the mouse vas deferens', Autonomic Neuroscience, vol. 149, no. 1-2, pp. 49-49. https://doi.org/10.1016/j.autneu.2009.05.074

Link to publication on Research at Birmingham portal

Publisher Rights Statement:

NOTICE: this is the author's version of a work that was accepted for publication in Autonomic Neuroscience. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Autonomic Neuroscience

Volume 149, Issues 1–2, 12 August 2009, Pages 49. DOI: http://dx.doi.org/10.1016/j.autneu.2009.05.074

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

Users may freely distribute the URL that is used to identify this publication.

. Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.

• User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?) Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

In both arteries, fluorescence ligand binding in the double knockouts was consistent with a "pure" population of the remaining subtype, as shown by elimination of binding by the relevant selective antagonist. Distribution of receptors on the cell surface and inside cells was not affected by the absence of the other subtypes. However, one difference was that the distribution of the alpha-1A-AR amongst the smooth muscle cells was more heterogeneous than for alpha-1D-AR. Repeating these experiments in wildtype or alpha-1B-KO mice demonstrated that both alpha-1A-AR and alpha-1D-AR were present and that eliminating them with selective competitors did not show a dominance in the number of each subtype present, irrespective of which was dominant in functional terms.

'Pure' alpha-1-AR-subtype pharmacology found in the double knockouts provides quantitative standards. Alpha-1A-AR and alpha-1D-AR produced additive responses, each dominating in different vessels, and did not significantly compensate in knockout mice. Alpha-1D-AR contributes to sensitivity to phenylephrine even in resistance arteries. There was no correlation between the presence of a given subtype as shown by fluorescent ligand binding sites and its contribution to vascular contraction: this suggests that the signalling process is more critical than the quantitative presence of the receptor. Similar distribution of fluorescent binding in the double KOs and WT indicates that in native SMC alpha-1-AR-subtypes do not influence each other's location. In conclusion, alpha-1-subtypes do not interact but provide independent alternative signals for autonomic regulation of the vasculature.

Acknowledgements: Support from the British Heart Foundation (PG/05/140/20094 and FS/04/035).

doi:10.1016/j.autneu.2009.05.073

S14.5 The effects of Δ^9 -tetrahydrocannabinol on sympathetic cotransmission in the mouse vas deferens

J.A.G. Kennard, A.R. Sachdev, J.S. Young, K.L. Brain (Department of Pharmacology, University of Oxford)

The mouse vas deferens is a well established model system for studying the effects of cannabinoids on sympathetic neuroeffector junctions [1]. This tissue is also frequently used to study cotransmission, as both noradrenaline (NA) and ATP are released from the nerve terminal varicosities (NTVs). However, investigation for differing effects of cannabinoids on the release and downstream actions of each of these neurotransmitters when pharmacologically isolated has not been carried out in the vas deferens. Therefore, we conducted experiments using Δ^9 -tetrahydrocannabinol (Δ^9 -THC) to investigate this.

Vasa deferentia were excised from male Balb/C mice (7-10 weeks) for use in contraction and confocal microscopy experiments. For contraction studies, vasa were suspended in 5 mL organ baths with electrical field stimulation (EFS) provided by two platinum ring electrodes. The noradrenergic and purinergic components of contraction were isolated using α , β -methylene ATP (1 μ M) and prazosin (100 nM) respectively; drugs were added by pipette into the organ bath. Δ^9 -THC (100 nM) caused a reduction in the peak amplitude of both noradrenergic and purinergic neurogenic contractions (10 pulses, 10 Hz, 0.5 ms width, supramaximal voltage) with a significant effect from 20 min (P < 0.01, n = 4-5) and reaching a maximal effect by 30-40 min. Interestingly, Δ^9 -THC caused a greater reduction in the amplitude of noradrenergic than purinergic contractions: at 40 min, noradrenergic contractions showed an average $72 \pm 14\%$ reduction compared to vehicle controls whereas purinergic contractions were reduced by $15 \pm 14\%$ only (P = 0.01). In agreement with previous studies, the effect of Δ^9 -THC upon neurogenic contractions was concentration-dependent and did not have a significant effect upon contractions caused by the application of the exogneous agonists phenylephrine (0.1–30 μ M) and $\alpha_n\beta$ methylene ATP (10 nM–1 μ M). For experiments using a range of EFS train lengths (1–200 pulses), Δ^9 -THC (100 nM) significantly increased the peak area for noradrenergic contractions at 200 pulses (P<0.05, n=6) with an average 134 \pm 37% increase in peak area compared to vehicle controls. No significant effect was observed upon purinergic contractions.

For imaging experiments, vasa were orthogradely filled with the Ca²⁺ indicator Oregon Green 488 BAPTA-1 10 kDa dextran to identify sympathetic terminals on the stage of a Leica NT confocal microscope [2]. Upon imaging electrically-induced Ca²⁺ transients in NTVs, Δ^9 -THC (100 nM) reduced the relative change in Δ F/F0 observed after a single field stimulus, compared to vehicle controls (*P*<0.0005). On average, Δ^9 -THC resulted in a 20 ± 3% reduction in the relative change of Δ F/F0 (*P*=0.0001), whereas vehicle produced no significant change 1 ± 3% increase (*P*>0.05).

These results show that Δ^9 -THC reduces the release of NA and ATP from sympathetic nerves in the mouse vas deferens, possibly by reducing Ca²⁺ influx into NTVs. The effect on NA appears to be greater; considering this and the increase in contraction area, it is tempting to speculate on an inhibitory action on the norepinerphrine transporter type 1 (NET-1).

[1] Thomas, A., Pertwee, R.G. 2006. The bioassay of cannabinoids using the mouse isolated vas deferens. Methods Mol Med 123, 191–207.

[2] Brain, K.L., Bennett, M.R. 1997. Calcium in sympathetic varicosities of mouse vas deferens during facilitation, augmentation and autoinhibition. J Physiol 502, 521–536.

doi:10.1016/j.autneu.2009.05.074

S15. Linking emotional stress to autonomic function S15.1 The activity of the sympathetic nervous system in conditions characterized by high emotional stress

E. Lambert, T. Dawood, G. Lambert (Human Neurotransmitters Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia)

Psychological factors, including everyday stress, major life events or the presence of depressive illness are now recognized as possible "triggers" for clinical cardiovascular events. Disturbed sympathetic nervous system (SNS) activity could possibly be one underlying mechanism linking psychological stress and cardiovascular disease.

We tested whether subjects with panic disorder and major depressive disorder (MDD) (but free of any cardiovascular conditions) presented with abnormal SNS activity. Microneurographic recordings of multi-unit MSNA in these subjects revealed normal rate of sympathetic nervous activity. However, by applying the technique of single unit MSNA recording (i.e., measuring single vasoconstrictor neuron activity) in subjects with panic disorder and MDD, we noted a disturbed sympathetic firing pattern in that there occurred a higher incidence of multiple firing of vasoconstrictor neurones during a sympathetic burst (increased salvoes). Such an irregular pattern of sympathetic nerve firing may possibly be relevant to the increased cardiac risk as the disturbed pattern of firing was paralleled by an increased release of noradrenaline from the cardiac sympathetic nerves.

We further investigated the link between stress and sympathetic nerve firing pattern in subjects with the metabolic syndrome and hypertension, who commonly, report high level of stress. We examined the SNS activity (multi-unit and single-unit MSNA) in relation to their underlying psychological stress [assessed by the State and Trait Anxiety score) and depression symptoms (assessed by using the Beck Depression Inventory II (BDI)]. Multi-unit MSNA was not